Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept

Molecular Therapy — Methods & Clinical Development(2020)10.1016/j.omtm.2020.11.012Source: DataRank Database

Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept is a research paper published in Molecular Therapy — Methods & Clinical Development (2020). On theSindex it has a DataRank of 0. It has been cited 20 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access20 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.90)OA: goldTopics (32)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Huimin Hu ORCID,Gabrielle Boyle ORCID,Elida Gomero ORCID,Rosario Mosca ORCID,Kartika Jayashankar

Live enrichment

PubMed:33426146 PMC:PMC7782203 OpenAlex:https://openalex.org/W3109059699

NIDDK NIH HHS

Grant: R01 DK095169

NIGMS NIH HHS

Grant: R01 GM104981

National Institutes of Health

Grant: 4R01DK095169-04

Gene Transfer for Galactosialidosis - Resub

National Institutes of Health

Grant: 5R01GM104981-03

Excessive Lysosomal Exocytosis Triggers Pathogenic Mechanisms in Sialidosis Mice

American Lebanese Syrian Associated Charities

Ultragenyx Pharmaceutical

National Institutes of Health

Assisi Foundation of Memphis

FWCI

0.90

Citation Percentile

0.7%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.cell.com/article/S2329050120302394/pdf

publisherhttp://www.cell.com/article/S2329050120302394/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2329050120302394?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2329050120302394?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.omtm.2020.11.012

Fields of Study

Lysosomal Storage Disorders ResearchTrypanosoma species research and implicationsCellular transport and secretion0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

Cathepsin AEnzyme replacement therapyNeuraminidaseLysosomal storage diseaseRecombinant DNAEnzymeBiochemistryCathepsinBiologyMolecular biologyMedicineChemistryPathologyDiseaseLysosomesErtΒ-galGalactosialidosisLysosomal GlycoproteinosisLysosomal Neu1Recombinant Protective Protein/Cathepsin AQH573-671QH426-470GeneticsOriginal ArticleCytology

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Life in Land